Precigen Q3 net loss widens to $24M; on track for Q4 PRGN-2012 BLA submission

PRECIGEN, INC.

2024-Q3 EPS reported -$0.41

Net loss of $24.0M ($0.09/sh) vs $19.8M loss YoY; nine-month loss $106.5M ($0.41/sh).
Completed pre-BLA meeting with FDA; full alignment on BLA content for PRGN-2012 in RRP; rolling submission planned Q4 2024.
Commercial and manufacturing readiness underway for potential 2025 launch of PRGN-2012.
Confirmatory trial for PRGN-2012 initiated; end of Phase 1b meeting for PRGN-3006 in AML expected early 2025.
August 2024 equity offering raised net $30.9M; workforce reduced by over 20%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.